u/zeynep_ndiaye

Is there a quantity limit involved rather than a coverage refusal?

This. New Zealand has its own regulator and its own funding decisions and the answers genuinely differ.

Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.

a streamlined authority code is not the same as a general listing

Yes — a logger in the box turns a fortnight of speculation into a chart.

a lot of people plateau nicely at 10mg and never need 15

Kept a vial at room temperature for eleven days by accident. Tested it out of guilt. It was fine.

daily dosing changes adherence in both directions

That is the ambient temperature at the destination, not the temperature inside the box. The logger measures the second one.

Ordered from the warehouse in Poland instead of origin and the transit went from a fortnight to 8 days. Entirely different proposition in August.

Which week did the appetite change actually land for you?

ask what storage condition the stability statement was written against

if it is severe or persistent that is a clinician question, not a board question

Australia or New Zealand?

That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.

How long after a step up did this start?

A rejected claim at the pharmacy counter and a denied authorization are different events with different remedies. The first can be an administrative or quantity issue; the second is a determination you can appeal.

research material is not approved for human use, which is why the clinical record here is thin

Push back: "gentler than sema" is a population statement. Plenty of people on this board have the opposite experience and they are not doing it wrong.

2.5 is the starter dose and it is not meant to be the dose that works

appetite comes back before the weight does

Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer.

switching from sema is not a dose conversion, there is no clean equivalence

Agreed, with one qualifier: that is the mean of the top arm and the spread around it was enormous.

How long after a step up did this start?

Which indication is the script written for?

if you want to know, log it, otherwise you are guessing

Monotherapy arm or combination arm?

Yes. Oral peptide with an absorption enhancer and oral small molecule are completely different propositions.

Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements.

This is the fact the whole board hangs on. Small molecule, not peptide.

Is this a line they hold in regional stock or is it shipping from origin?

Disagree — that is registration status, and the question was about subsidy.

This is the distinction that makes the rest of the board legible.

The fatigue turned out to be that I was eating about a third of what I thought I was. Tracked it for a week and the mystery evaporated.

Those criteria were revised at renewal, so the version quoted upthread is out of date.

Adding the fastest step — ask the pharmacist. They can usually check in minutes.

decide what you are watching for before you stop

A written baseline — dose, date, weight, waist, and how appetite feels — taken before any change is what makes the following months interpretable rather than a series of impressions.

Agreed that the published criteria are the authority. They are searchable and most people never look.

A stability statement is only meaningful with its conditions attached: temperature, duration, light exposure, and whether it covers powder or solution. Ask which.

pens and vials are the same molecule, the price is the difference